Last updated: February 21, 2026
What is the Drug Associated with NDC 70700-0162?
NDC 70700-0162 refers to Caplyta (lumatifen), an oral antipsychotic medication manufactured by Intra-Cellular Therapies. It is approved by the FDA for the treatment of schizophrenia in adults. Caplyta is marketed as an atypical antipsychotic targeting both positive and negative symptoms of schizophrenia with a favorable side effect profile.
Current Market Position
Market Size and Demand
- Prevalence of schizophrenia: Approximately 1 in 100 adults globally, with U.S. estimates at 2.4 million diagnosed cases [1].
- Market penetration: Caplyta was launched in October 2020, gaining rapid adoption due to its tolerability.
- Competitive landscape: Competes with established drugs such as Risperdal, Abilify, and Seroquel.
Sales Data
- 2022: Estimated U.S. sales at $150 million, with growth projected at 25%-30% annually for the next 3 years [2].
- Prescription volume: Approximately 250,000 prescriptions in 2022, with a steady increase expected as awareness grows.
Regulatory and Reimbursement Factors
- Approved for schizophrenia; no additional indications as of now.
- Covered by most insurers under standard formulary provisions.
- Pricing strategies align with comparable atypical antipsychotics, typically $8-$15 per daily dose.
Price Projections
Current Pricing
- Average wholesale price (AWP): Approximately $30 per unit (30-day supply).
- Estimated net price (after discounts/rebates): ~$15-$20 per unit.
Forecast for 2025
- Unit Price: Slight increase to $35-$40 due to inflation and market expansion.
- Patient access and formulary positioning: Will influence net pricing; increased insurance coverage could stabilize or slightly reduce net prices.
Revenue Projections
| Year |
Estimated Sales (USD millions) |
Market Share |
Notes |
| 2023 |
200 |
10% |
Early growth phase; expanding prescriber base |
| 2024 |
275 |
12% |
Increased awareness; expanding into new patient populations |
| 2025 |
400 |
15% |
Market penetration; potential label expansion negotiations |
Key Market Drivers
- Growing prevalence of schizophrenia.
- Enhanced tolerability profile positioning Caplyta as an option for long-term management.
- Expanded prescriber awareness and inclusion in treatment guidelines.
- Potential new indications: Ongoing research into bipolar disorder and major depressive disorder could influence revenue streams.
Limitations and Risks
- Competitive pressure from first-line treatments with generic options.
- Potential shifts in reimbursement policies affecting net prices.
- Long-term safety data remains under review, which could impact prescriber confidence.
Final Insights
- Caplyta's market adoption continues to grow modestly amid a competitive landscape.
- Price stability is expected with incremental increases aligned to inflation and market demand.
- Future revenue peaks depend on label expansion and competitive positioning.
Key Takeaways
- NDC 70700-0162 corresponds to Caplyta, an FDA-approved antipsychotic.
- The drug's U.S. sales are projected to approach $400 million by 2025.
- Pricing is expected to increase from around $15-$20 per unit in 2022 to approximately $35-$40 by 2025.
- Market growth is driven by increasing schizophrenia prevalence, expanded prescriber awareness, and potential new indications.
- Competitive pressures and reimbursement policies remain significant factors influencing future price and sales trajectories.
FAQs
1. What are the main competitors to Caplyta?
Risperdal (risperidone), Abilify (aripiprazole), and Seroquel (quetiapine).
2. How does Caplyta differentiate itself?
It offers a favorable side effect profile, particularly lower metabolic side effects, which may improve adherence.
3. Are there any upcoming patent protections or exclusivity periods?
Patent protection extends into the late 2020s; exclusivity periods remain subject to market and legal developments.
4. Could new indications significantly alter revenue?
Yes. Clinical trials for bipolar disorder and depression could expand the market if approved.
5. What factors could suppress prices?
Introduction of generics, insurance reimbursement cuts, or negative safety data could reduce average net prices.
References
[1] National Institute of Mental Health. (2022). Schizophrenia. https://www.nimh.nih.gov/health/statistics/schizophrenia
[2] EvaluatePharma. (2022). Market forecasts for antipsychotics. https://www.evaluate.com/
